Avid Bioservices, Inc.

  • Market Cap: Micro Cap
  • Industry: Biotechnology
  • ISIN: US05368M1062
USD
12.49
0.00 (0.00%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

0

Shareholding (Oct 2024)

FII

8.54%

Held by 86 FIIs

DII

40.92%

Held by 61 DIIs

Promoter

0.28%

How big is Avid Bioservices, Inc.?

22-Jun-2025

As of Feb 06, Avid Bioservices, Inc. has a market capitalization of 798.90 million and reported net sales of 150.44 million with a net profit loss of 152.05 million over the last four quarters.

Market Cap: As of Feb 06, Avid Bioservices, Inc. has a market capitalization of 798.90 million, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Avid Bioservices reported net sales of 150.44 million. However, the company experienced a net profit loss of 152.05 million during the same period.<BR><BR>Balance Sheet Snapshot: As of April 2024, Avid Bioservices reported shareholder's funds of 60.89 million and total assets amounting to 336.56 million.

Read More

What does Avid Bioservices, Inc. do?

22-Jun-2025

Avid Bioservices, Inc. is a contract development and manufacturing organization specializing in biopharmaceutical products from mammalian cell culture. As of October 2024, it reported net sales of $33 million and a net loss of $17 million, with a market cap of $798.90 million.

Overview: <BR>Avid Bioservices, Inc. is a contract development and manufacturing organization (CDMO) focused on the development and CGMP manufacturing of biopharmaceutical products derived from mammalian cell culture, operating within the biotechnology industry and classified as a micro-cap company.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 33 Million (Quarterly Results - Oct 2024) <BR>Most recent Net Profit: -17 Million (Quarterly Results - Oct 2024) <BR>Market-cap: USD 798.90 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 98.15% <BR>Debt Equity: 2.72 <BR>Return on Equity: -339.34% <BR>Price to Book: 17.83<BR><BR>Contact Details: <BR>Address: 2642 Michelle Dr Ste 200, TUSTIN CA: 92780-7019 <BR>Tel: ['1 714 5086100', '1 415 6757401'] <BR>Fax: 1 714 8385817 <BR>Website: http://avidbio.com/

Read More

Should I buy, sell or hold Avid Bioservices, Inc.?

22-Jun-2025

Who are in the management team of Avid Bioservices, Inc.?

22-Jun-2025

As of March 2022, the management team of Avid Bioservices, Inc. includes Dr. Joseph Carleone (Independent Non-Executive Chairman), Mr. Nicholas Green (President and CEO), Mr. Richard Hancock, Mr. Mark Bamforth, Dr. Catherine Mackey, and Mr. Gregory Sargen (all Independent Directors). They oversee the company's strategic direction and operations.

As of March 2022, the management team of Avid Bioservices, Inc. includes the following individuals:<BR><BR>- Dr. Joseph Carleone, who serves as the Independent Non-Executive Chairman of the Board.<BR>- Mr. Nicholas Green, who is the President, Chief Executive Officer, and a Director.<BR>- Mr. Richard Hancock, who is a Director.<BR>- Mr. Mark Bamforth, who is an Independent Director.<BR>- Dr. Catherine Mackey, who is also an Independent Director.<BR>- Mr. Gregory Sargen, who serves as an Independent Director. <BR><BR>This team is responsible for guiding the company's strategic direction and operations.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
1

With a fall in Net Profit of NAN%, the company declared Very Negative results in Oct 24

  • The company has declared negative results for the last 9 consecutive quarters
  • NET PROFIT(HY) At USD -22.94 MM has Grown at -97.03%
  • ROCE(HY) Lowest at -133.29%
  • DEBT-EQUITY RATIO (HY) Highest at 383.65 %
2

Risky - Not traded in last 10 days

stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Biotechnology

stock-summary
Market cap

USD 799 Million (Micro Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

98.15%

stock-summary
Debt Equity

2.72

stock-summary
Return on Equity

-339.34%

stock-summary
Price to Book

17.83

Revenue and Profits:
Net Sales:
33 Million
(Quarterly Results - Oct 2024)
Net Profit:
-17 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
18.5%
0%
18.5%
6 Months
18.84%
0%
18.84%
1 Year
99.2%
0%
99.2%
2 Years
-22.85%
0%
-22.85%
3 Years
-35.52%
0%
-35.52%
4 Years
-31.49%
0%
-31.49%
5 Years
91.56%
0%
91.56%

Avid Bioservices, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News
Icon
No Recent News for the Company
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
18.50%
EBIT Growth (5y)
-218.87%
EBIT to Interest (avg)
0.56
Debt to EBITDA (avg)
2.16
Net Debt to Equity (avg)
2.72
Sales to Capital Employed (avg)
0.50
Tax Ratio
100.00%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
12.09%
ROE (avg)
18.60%
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
17.83
EV to EBIT
-45.19
EV to EBITDA
-118.09
EV to Capital Employed
5.52
EV to Sales
6.12
PEG Ratio
NA
Dividend Yield
98.15%
ROCE (Latest)
-12.22%
ROE (Latest)
-339.34%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Mildly Bullish
RSI
Bearish
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
No Trend
No Trend
OBV
Bullish
Bullish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Oct 2024stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 68 Schemes (50.15%)

Foreign Institutions

Held by 86 Foreign Institutions (8.54%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Oct'24 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Oct 2024 is -16.67% vs -6.51% in Jul 2024",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Oct 2024 is -216.36% vs 95.53% in Jul 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Oct'24",
        "Jul'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "33.50",
          "val2": "40.20",
          "chgp": "-16.67%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-8.70",
          "val2": "0.40",
          "chgp": "-2,275.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "3.30",
          "val2": "2.50",
          "chgp": "32.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-17.40",
          "val2": "-5.50",
          "chgp": "-216.36%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-377.20%",
          "val2": "-61.10%",
          "chgp": "-31.61%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Apr'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Apr 2024 is -6.30% vs 24.83% in Apr 2023",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Apr 2024 is -47,033.33% vs -99.77% in Apr 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Apr'24",
        "Apr'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "139.90",
          "val2": "149.30",
          "chgp": "-6.30%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-7.60",
          "val2": "10.90",
          "chgp": "-169.72%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "4.30",
          "val2": "3.00",
          "chgp": "43.33%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-1.90",
          "val2": "-0.10",
          "chgp": "-1,800.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-140.80",
          "val2": "0.30",
          "chgp": "-47,033.33%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-133.50%",
          "val2": "24.80%",
          "chgp": "-15.83%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Oct'24 - QoQstock-summary
Oct'24
Jul'24
Change(%)
Net Sales
33.50
40.20
-16.67%
Operating Profit (PBDIT) excl Other Income
-8.70
0.40
-2,275.00%
Interest
3.30
2.50
32.00%
Exceptional Items
0.00
0.00
Consolidate Net Profit
-17.40
-5.50
-216.36%
Operating Profit Margin (Excl OI)
-377.20%
-61.10%
-31.61%
USD in Million.
Direction Arrows
Net Sales

QoQ Growth in quarter ended Oct 2024 is -16.67% vs -6.51% in Jul 2024

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Oct 2024 is -216.36% vs 95.53% in Jul 2024

Annual Results Snapshot (Consolidated) - Apr'24stock-summary
Apr'24
Apr'23
Change(%)
Net Sales
139.90
149.30
-6.30%
Operating Profit (PBDIT) excl Other Income
-7.60
10.90
-169.72%
Interest
4.30
3.00
43.33%
Exceptional Items
-1.90
-0.10
-1,800.00%
Consolidate Net Profit
-140.80
0.30
-47,033.33%
Operating Profit Margin (Excl OI)
-133.50%
24.80%
-15.83%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in year ended Apr 2024 is -6.30% vs 24.83% in Apr 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Apr 2024 is -47,033.33% vs -99.77% in Apr 2023

stock-summaryCompany CV
About Avid Bioservices, Inc. stock-summary
stock-summary
Avid Bioservices, Inc.
Biotechnology
Avid Bioservices, Inc. is a contract development and manufacturing organization (CDMO). The Company is focused on development and Current Good Manufacturing Practices (CGMP) manufacturing of biopharmaceutical products derived from mammalian cell culture. The Company provides a range of process development, CGMP clinical and commercial manufacturing services for the biotechnology and biopharmaceutical industries. The Company’s services include CGMP clinical and commercial product manufacturing, purification, bulk packaging, stability testing and regulatory strategy, submission and support. The Company also provides process development activities, including cell line development and optimization, cell culture and feed optimization, analytical methods development and product characterization.
Company Coordinates stock-summary
Company Details
2642 Michelle Dr Ste 200 , TUSTIN CA : 92780-7019
stock-summary
Tel: 1 714 50861001 415 6757401
stock-summary
Registrar Details